Form 4: Imunon Director James E. Dentzer Acquires Stock Options in Lieu of Cash Compensation

Director James E. Dentzer acquired 3,634 stock options of Imunon, Inc. in lieu of cash for a portion of board fees.

Summary

• On September 10, 2024, James E. Dentzer, a director of Imunon, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on September 6, 2024, where Dentzer acquired 3,634 stock options.
• These options were granted in lieu of cash compensation for a portion of board fees.
• The exercise price of the options is $1.04, which was the closing price of Imunon's common stock on the grant date.
• The options vest in three tranches: 1/2 on the date of grant, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.
• The options expire on September 6, 2034.
• Following the reported transaction, Dentzer directly owns 17,301 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options to a director is a common practice and aligns interests with shareholders. The fact that the options were granted in lieu of cash is a positive for the company's cash flow.

Positives

• The acquisition of stock options by a director aligns their interests with those of the shareholders.
• Granting options in lieu of cash conserves the company's cash resources.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of director compensation packages in similar small-cap biotechnology companies.
• The vesting schedule of 1/2 on the date of grant, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary is a fairly standard vesting schedule.
• Comparable companies such as Celldex Therapeutics and BioCryst Pharmaceuticals also utilize stock options as part of their director compensation.

Related Party Transactions

• The grant of stock options to James E. Dentzer, a director, is a related party transaction.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with theirs.
• The company benefits from conserving cash by granting options in lieu of cash compensation.

Key Dates

Keywords

Form 4, Imunon, Director, Stock Options, Beneficial Ownership, Compensation